[HTML][HTML] Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - Drugs, 2021 - Springer
Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
[HTML][HTML] Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - Drugs, 2021 - ncbi.nlm.nih.gov
Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - Drugs, 2021 - europepmc.org
Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - Drugs, 2021 - search.ebscohost.com
Abstract Background: ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First‑Line Treatment in Patients with Advanced Non‑Small‑Cell Lung …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - Drugs, 2021 - search.proquest.com
Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …